Key result
The novel gadolinium-based MRI contrast agent P947 showed preferential accumulation in atherosclerotic lesions compared with Gd-DOTA, facilitating discrimination of MMP-rich plaques.
Why the study?
Does the novel MRI contrast agent P947 improve the visualization and characterization of MMP-rich atherosclerotic plaques compared to Gd-DOTA in preclinical models?
Population
In vitro models, in vivo ApoE-/- mice, ex vivo hyperlipidemic rabbits, and human carotid artery…
Comparison
P947 (novel gadolinium-based MRI contrast agent) vs Gd-DOTA (nontargeted reference compound)
Design
Preclinical
Authors
Loading...
P947 shows no immediate clinical utility; hypothesis-generating for human MMP-rich plaque imaging pending prospective trials.
Does the novel MRI contrast agent P947 improve the visualization and characterization of MMP-rich atherosclerotic plaques compared to Gd-DOTA in preclinical models?
The novel MRI contrast agent P947 can specifically target activated MMPs, potentially allowing noninvasive identification of vulnerable atherosclerotic plaques.
Lancelot et al. (2008) studied Atherosclerosis. P947 (gadolinium-based MRI contrast agent) vs. Gd-DOTA was evaluated on Preferential accumulation in atherosclerotic lesions. The novel gadolinium-based MRI contrast agent P947 showed preferential accumulation in atherosclerotic lesions compared with Gd-DOTA, facilitating discrimination of MMP-rich plaques.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: